化合物SB 204990
化合物SB 204990 性质
| 熔点 | 87-89 °C |
|---|---|
| 沸点 | 571.6±40.0 °C(Predicted) |
| 密度 | 1.332±0.06 g/cm3(Predicted) |
| 溶解度 | DMF：30mg/mL； DMF:PBS(pH7.2)(1:2)：0.33mg/ml； DMSO：20mg/mL；乙醇：1mg/mL |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 4.33±0.10(Predicted) |
| 颜色 | 白色至米白色 |
| InChI | InChI=1/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/s3 |
| InChIKey | YTRNLFYTHYWDAU-RVFWCEGZNA-N |
| SMILES | O1[C@@H](CCCCCCC2=CC=C(Cl)C=C2Cl)C[C@@](O)(CC(O)=O)C1=O |&1:1,17,r| |
化合物SB 204990 用途与合成方法
ACLY.
SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels.
SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels.
化合物SB 204990 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-16450 | 化合物SB 204990 | 154566-12-8 | 10mM * 1mLin DMSO | 1320 |
| 2024-04-30 | HY-16450 | 化合物SB 204990 | 154566-12-8 | 10mg | 2040 |
